AR007057A1 - Medicamento de interferon oromucosal y uso de interferon en su manufactura - Google Patents

Medicamento de interferon oromucosal y uso de interferon en su manufactura

Info

Publication number
AR007057A1
AR007057A1 ARP970101923A ARP970101923A AR007057A1 AR 007057 A1 AR007057 A1 AR 007057A1 AR P970101923 A ARP970101923 A AR P970101923A AR P970101923 A ARP970101923 A AR P970101923A AR 007057 A1 AR007057 A1 AR 007057A1
Authority
AR
Argentina
Prior art keywords
interferon
oromucosal
medication
manufacture
mammal
Prior art date
Application number
ARP970101923A
Other languages
English (en)
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN9765A external-priority patent/AUPN976596A0/en
Priority claimed from AUPO3959A external-priority patent/AUPO395996A0/en
Priority claimed from AUPO4387A external-priority patent/AUPO438796A0/en
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of AR007057A1 publication Critical patent/AR007057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El uso del interferón en la preparación de un medicamento para contacto oromucosal para estimular los mecanismos de defensa o una respuesta inmune enun mamífero con una cantidad de interferón que excede aquella que podría ejercer unarespu esta patológica cuando se administra parentalmente. Además,describe dicho medicamento que lo contiene.
ARP970101923A 1996-05-09 1997-05-08 Medicamento de interferon oromucosal y uso de interferon en su manufactura AR007057A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
AUPO3959A AUPO395996A0 (en) 1996-12-03 1996-12-03 Stimulation of host defence mechanisms
AUPO4387A AUPO438796A0 (en) 1996-12-24 1996-12-24 Method of treatment

Publications (1)

Publication Number Publication Date
AR007057A1 true AR007057A1 (es) 1999-10-13

Family

ID=49381771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101923A AR007057A1 (es) 1996-05-09 1997-05-08 Medicamento de interferon oromucosal y uso de interferon en su manufactura

Country Status (2)

Country Link
KR (1) KR100399500B1 (es)
AR (1) AR007057A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111514123A (zh) * 2020-02-17 2020-08-11 江苏伯克生物医药股份有限公司 替洛酮类似物在抗病毒感染中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100735571B1 (ko) * 2006-01-24 2007-07-06 황수원 실리콘과 에프알피를 이용한 인조 초가 지붕 및 그 제조방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111514123A (zh) * 2020-02-17 2020-08-11 江苏伯克生物医药股份有限公司 替洛酮类似物在抗病毒感染中的应用

Also Published As

Publication number Publication date
KR100399500B1 (ko) 2003-12-18
KR20000010881A (ko) 2000-02-25

Similar Documents

Publication Publication Date Title
ES527805A0 (es) Sistema de bombeo por inyeccion para administrar liquidos intra-venosos e intra-arteriales sobre el cuerpo de un paciente.
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
PE19496A1 (es) Formulacion de analogo de insulina humana
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
ES2150889T1 (es) Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ES2075468T3 (es) Vehiculos de suministro de farmacos suspendidos en un portador perfluorado no acuoso.
DE69109557T2 (de) Überzogene feste Arzneiform mit Verabreichungsmöglichkeit im Dickdarm.
CO5060484A1 (es) Braga absorbente
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
DE3688532T2 (de) Pharmazeutische darreichungsform mit verzoegerter abgabe.
BR9814592B1 (pt) composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DE3681582D1 (de) Pharmazeutische zubereitung mit abgabeeigenschaften.
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
DE68908456T2 (de) Matrix zur Wirkstoffabgabe.
DE69332082D1 (de) Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt
CO5050297A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
SV1998000065A (es) Formulas estables de insulina ref. x-10675
ES2119411T5 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
HK1079455A1 (en) Medical active agent patch optically less visible on skin
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.